Infectious disease development is becoming increasingly complex. Sponsors need earlier answers, deeper biological insights, and greater confidence in development decisions long before large-scale clinical trials begin. This eBook explores how human challenge studies, advanced laboratory science, biomarker strategies, and next-generation technologies are helping accelerate development timelines while generating more meaningful evidence.
From controlled human infection models and respiratory challenge studies to next-generation sequencing (NGS), specialty laboratory services, biomarker discovery, and translational science, the eBook demonstrates how integrating scientific expertise with clinical research can help sponsors make smarter decisions earlier in development.
Drawing on insights from hVIVO's scientific leaders and real-world examples across RSV, hMPV, SARS-CoV-2 and other respiratory pathogens, this resource explores the evolving approaches helping to shape the future of infectious disease research.
In this eBook, discover:
- Why human challenge studies are becoming a powerful tool in infectious disease development, enabling faster proof-of-concept data generation, smaller study populations, and earlier efficacy insights.
- How advanced laboratory technologies such as NGS, molecular diagnostics and biomarker analysis are strengthening decision-making in early-phase research.
- The role of specialty laboratories in infectious disease development, and how integrated scientific capabilities can support vaccine, antiviral and biomarker programmes.
- How respiratory challenge models are evolving, including the development of next-generation RSV and hMPV challenge models.
- The latest insights from RSV and SARS-CoV-2 research, including viral dynamics, maternal vaccination strategies and novel biomarkers that may improve diagnosis and patient stratification.
- How integrated scientific, laboratory and clinical expertise can help reduce development risk and accelerate programme progression.
.png)
Accelerate Better Decisions in Infectious Disease Development
Download the eBook to explore the technologies, scientific approaches and clinical strategies shaping the future of infectious disease research.
Meet the Author
Dr Andrew Catchpole is Chief Scientific Officer at hVIVO and a recognised expert in human challenge studies. With a background in virology and decades of experience supporting infectious disease research, he has played a leading role in the development of influenza, RSV, HRV and SARS-CoV-2 challenge models. Through his scientific leadership and consultancy expertise, Andrew helps sponsors design studies, develop analytical strategies and generate the evidence needed to advance innovative vaccines, antivirals and immunomodulators.
Our Accreditations
Good Clinical Practice (GCP)
Good Clinical Practice (GCP) is an international ethical and scientific quality standard; for designing, conducting, recording and reporting trials. Ensuring participant safety prevails over the interests of science and society.
Human Tissue Authority (HTA)
hVIVO is accredited by the Human Tissue Authority (HTA), meaning that we have been recognized by the HTA as compliant with standards and regulations for the ethical and legal removal, storage, and use of human tissue. A HTA license is essential, as hVIVO handles human tissue for various research purposes.
Good Clinical Laboratory Practice (GCLP)
All clinical trials comply with GCP and/or GCP for Laboratories (GCLP) guidance. Human Challenge Agent-only clinical studies that do not involve IMP also comply with GCP/GCLP.
hVIVO is a UKAS accredited Testing Laboratory No. 27882
